|Primary analysis complete
|Study Start Date:
|Study Made Public:
A worldwide, Phase I, dose-escalating study of the safety, tolerability, and immunogenicity of a 3-dose regimen of the MRKAd5 HIV-1 gag vaccine in healthy adults
HVTN 050 (Merck V520-018) is a Phase I clinical trial to evaluate the safety and immunogenicity of MRKAd5 HIV-1 gag (Ad5).
Sign in to see full information about this study and to download study data.
ProductsProduct info coming soon!
No integrated data is available for this study.
No non-integrated data is available for this study.